Lebrikizumab
Based on 1 publication(s) in Google Scholar
Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.90%
- CAS. Nr.: 953400-68-5
- Molecular Weight:145.318 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Lebrikizumab
More
Biologische Aktivität
Human IgG4 kappa
Human
|
IL-13 |
Lebrikizumab (500 μg/mL or 1 mg/mL, 24 h) effectively inhibits the IL-13-elicited neuronal sensitization responses to each of the 3 pruritogens in vitro[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Lebrikizumab (HY-P99025) neutralizes Recombinant Human IL-13 (HY-P70568) induced proliferation in the TF-1 human erythroleukemic cell line. The Neutralization Dose (ND50) for this effect is 0.9529 μg/mL in the presence of 10 ng/mL Recombinant Human IL-13. -
Loaded Lebrikizumab on AHC2 biosensor, can bind IL-13 Protein, Human (HEK293, His, HY-P70568) with an affinity constant of 7.283E-10 M as determined in BLI assay.
Chemical Information
-
CAS. Nr. 953400-68-5
-
Appearance Liquid
-
Molecular Weight 145.318 kDa
-
Color Colorless to light yellow
-
SMILES
[Lebrikizumab]
-
Synonyms
TNX-650; MILR1444A; RG3637
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
bioRxiv
Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors. [Abstract]2025 Jan 25:2025.01.24.631210. PMID: 39896575
Reinheit & Dokumentation
-
Data Sheet (258 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Jonathan Corren, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011 Sep 22;365(12):1088-98. [Content Brief]
[2]. Loh TY, et al. Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis. J Asthma Allergy. 2020 Feb 11;13:109-114. [Content Brief]
[3]. Miron Y, et al. Mechanistic insights into the antipruritic effects of lebrikizumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2022 Sep;150(3):690-700. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Powered by Bioz